Compare AbbVie Inc (ABBV) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? AbbVie Inc trades at $253.6 (market cap $449.91B), while Vanguard Information Technology Index Fund ETF trades at $115.15. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Information Technology Index Fund ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VGT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $125.77 |
52-Week Low | $184.85 | $83.59 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
The Vanguard Information Technology ETF (VGT) trades at $116.37, up 1.51% on the day, with technical indicators showing a mixed but slightly bullish bias. The fund recently executed an 8-for-1 stock split and maintains a low 0.09% expense ratio, positioning it as a cost-efficient vehicle for broad tech exposure. Financial media sentiment is generally positive, highlighting VGT's strong long-term track record and diversification benefits compared to more concentrated tech ETFs.
The outlook for VGT is tied to the broader technology sector's performance, particularly hyperscaler capital expenditure and semiconductor cycles. Key opportunities include exposure to AI-driven growth through a diversified portfolio. Primary risks involve sector concentration, market volatility, and potential valuation pressures if tech earnings growth decelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
